Please assess the completion status of the following clinical trial:

Trial Title: Consistency Lots Vaccine Study (V260-009)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants~Exclusion Criteria:~* History of abdominal disorders from a birth defect, intussusception, or abdominal surgery~* Known or suspected problems with the immune system~* Fever at time of immunization~* Prior administration of a rotavirus vaccine~* History of known prior rotavirus disease, chronic diarrhea, or failure to thrive.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- RotaTeq™ Lot 1 (Type: EXPERIMENTAL): \~8.81 X 10\^7 IU/Dose of RotaTeq™
- RotaTeq™ Lot 2 (Type: EXPERIMENTAL): \~8.01 X 10\^7 IU/Dose of RotaTeq™
- RotaTeq™ Lot 3 (Type: EXPERIMENTAL): \~6.91 X 10\^7 IU/Dose of RotaTeq™
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).